What it sells
Enabling T cell immunotherapy discovery, development and manufacturing
Business model breakdown
Buyer: who owns the budget?
Cell therapy R&D and process development groups at pharma/biotech (site cites 3 top pharmaceutical companies using Hydropore).
Trigger: what makes them buy now?
Gene transfer step is the bottleneck in cell therapy manufacturing; viral transduction and electroporation add cost, lead time and regulatory risk.
Workflow: what inputs become what output?
Hydropore uses microfluidic vortex shedding on a 5x10mm chip (>50M cells, 2-4M cells/sec) to deliver small molecules, mRNA, CRISPR RNPs into immune cells for discovery, development and manufacturing.
Economics: what it saves and how it charges
UnverifiedSale of Hydropore devices/chips (site: "Order Hydropore") and licensing/partnership for manufacturing.
Distribution: how it reaches customers
Direct orders and "Partner with Us"; no self-serve pricing.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2017 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.